A CardioAdvocate Phenotype
Case Presentation: Bob Harper's Heart Attack
The story of Bob Harper's heart attack on February 12, 2017 brought to light two very important aspects of ASCVD risk:
- Optimizing modifiable risk factors alone does not eliminate the risk of heart attack. You can't "run" away from your genetics.
- Lipoprotein (a) or Lp(a) - pronounced "Lp little a" - warrants screening and treatment.
Many know Bob Harper as the celebrity personal trainer from NBC's reality TV show The Biggest Loser. As a fitness expert, Bob Harper was the epitome of health - eating healthy and exercising regularly. But at age 51 Bob suffered a massive heart attack in the gym during a workout. Fortunately there was a doctor in the room and he received prompt CPR and defibrillation from an available AED.
Bob reportedly had normal cholesterol but his Lp(a) was "perilously high" (The Harmful Blood Particle You've Never Heard Of — Cleveland HeartLab). About 90% of Lp(a) particle numbers are determined by genetics. Bob had a family history of heart disease - his mother died of a heart attack. But he's not alone - about 1 in 5 of us have elevated Lp(a) levels (≥ 50 mg/dL or ≥ 125 nmol/L), making it the most common familial lipid abnormality causal to atherosclerosis.
Flying Under the Radar
If you've never been tested and you're asking "What is Lp(a)?" - you're not alone. Fewer than 2% of those who have ever had a lipid panel have also been tested for Lp(a), and shockingly, < 3% of those with established heart disease (Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States).
Routine testing of Lp(a) in those with established ASCVD can better identify those with heightened risk for recurrent events and assist in management (Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank).
The high prevalence of this risk factor (1.4 billion globally), coupled with the mind-blowing lack of awareness, makes this phenotype particularly dangerous. Lipoprotein(a) is causal to both atherosclerosis and calcific aortic stenosis.
Lp(a) is a Continuous Causal Risk Factor for ASCVD Events
As its concentration increases linearly, so does the risk for ASCVD events. When added to polygenic risk scores (PRS), those with the highest PRS and high Lp(a) (> 125 nmol/L) had a 5 times higher risk of ASCVD event compared to low PRS and low Lp(a) (Contribution of Lipoprotein(a) to Polygenic Risk Prediction of Coronary Artery Disease: A Prospective UK Biobank Analysis).
Lp(a) is Atherogenic
Lp(a) is a member of the "atherogenic lipoprotein" species. It's an LDL-like particle with an apolipoprotein(a) attached by a disulfide bond to ApoB. It not only delivers cholesterol, but also oxidized phospholipids on its membrane, into the artery wall.
Lp(a) is Prothrombotic
Lp(a) may promote clotting more readily. Those who rupture a plaque may be more prone to catastrophic clotting events. Lp(a) has homologous regions to plasminogen - having too much Lp(a) may prevent plasminogen from breaking down clots when it should.
Lp(a) is Causal to Calcific Aortic Stenosis
Lp(a) increases expression of vascular and valvular calcification genes. Those above the 80th percentile (50 mg/dL) have a 3x higher risk of aortic stenosis. Aortic stenosis is predicted to increase by > 300% by 2050 (Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement).
Lp(a) Risk is Familial and Common
Lp(a) particle number is highly inheritable, with the apo(a) gene accounting for > 90% of variability. Since high Lp(a) affects 1 in 5 of us, it represents the most common genetic lipid abnormality causal to atherosclerosis and aortic stenosis.
Lp(a) Screening is Recommended — Now with Class I Evidence (2026)
The 2026 ACC/AHA/NLA Dyslipidemia Guidelines recommend measuring Lp(a) at least once in all adults (Class 1, Level of Evidence B-NR). This is a major shift from prior guidance — universal screening is now guideline-directed, not optional. The European Society of Cardiology and the Canadian Cardiovascular Society recommend screening the entire population for elevated Lp(a) at least once. See our phenotype "Hiding in Plain Sight - Familial Hypercholesterolemia."
In an effort to increase awareness, Bob partnered with AstraZeneca for Survivors Have Heart with his essay Moving Forward as a Heart Attack Survivor. If your Lp(a) is elevated, consider cascade screening for family members. March 24th is National Lp(a) Day.
CardioAdvocate Checklist
Patient Questions - Know Your Status
If Lp(a) is Elevated - Action Items
Questions to Ask Your Clinician
- "Has my Lp(a) ever been checked?"
- "Given my family history of heart disease, should I have my Lp(a) tested?"
- "If my Lp(a) is elevated, should my children and siblings be tested too?"
- "Given my Lp(a) level, are there clinical trials for new Lp(a)-lowering drugs I might qualify for?"
- "If I have heart disease and elevated Lp(a), should I be on a PCSK9 inhibitor?"
- "How aggressively should we treat my other risk factors given my elevated Lp(a)?"
Deep Dive: Understanding Lp(a) and the 2026 Guideline Shift
The Game-Changer: 2026 ACC/AHA/NLA Class 1 Universal Screening
The 2026 ACC/AHA/NLA Dyslipidemia Guidelines represent a paradigm shift in how we approach Lp(a). For the first time, the ACC/AHA explicitly recommend measuring Lp(a) at least once in ALL adults as a Class 1 recommendation (Level of Evidence B-NR). This is not a "risk enhancer" buried in a sidebar — it's now foundational screening, equivalent to measuring LDL-C.
In 2018, Lp(a) was listed as a "risk enhancer" with no formal testing recommendation. Today, with better epidemiologic evidence and mechanistic understanding, universal screening is now the standard. The ESC achieved consensus on this in 2019; the CCS (Canadian) guidelines already supported it; and now the ACC/AHA join the transatlantic consensus.
Updated Threshold Definitions (2026)
The 2026 guidelines clarify and standardize Lp(a) thresholds:
- Elevated Lp(a): ≥ 125 nmol/L or ≥ 50 mg/dL
- Very high Lp(a): ≥ 200 nmol/L or ≥ 75 mg/dL
- Critical note: nmol/L and mg/dL are NOT interchangeable. The discrepancy exists because apo(a) isoform size varies substantially between individuals. Immunoturbidimetric assays typically report mg/dL; immunonephelometric assays may report nmol/L. Always confirm which measurement unit your lab is using.
What is Lp(a)?
Think of Lp(a) as an LDL particle (cholesterol-rich lipoprotein) with an apolipoprotein(a) covalently bound to apolipoprotein B by a disulfide bridge.
Apo(a) is produced in the hepatocyte (liver cell). Apo(a) size is highly variable due to "Kringle repeats" - molecular structures that look like a Kringle Danish pastry. Within the domain KIV² there may be just a few or multiple copies, determining particle size. There's an inverse relationship: fewer repeats = more particles. Levels can vary up to 1000-fold between individuals. The Apo(a) gene accounts for 90% of variability.
Atherogenic Mechanism
While Lp(a) is an LDL-like particle capable of trafficking cholesterol esters and infiltrating the endothelial wall, the majority of its contribution to atherosclerosis comes from oxidized phospholipids on its polar membrane. Pound for pound, oxidized phospholipids contribute more to inflammation through cell signaling rather than plaque accumulation.
In this study, Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis, Lp(a) is about 6 times more atherogenic than LDL on a per-particle basis.
As for its ApoB contribution, there is a 1:1 relationship of apoB to Lp(a). If Lp(a) is 125 nmol/L, this means the apoB contribution from Lp(a) is also 125 nmol/L. Dividing by conversion factor 19.49 gives an apoB of 6.4 mg/dL attributable to Lp(a). But even with low LDL-C, very high Lp(a) remains a risk factor.
Thrombogenic Mechanism
Apolipoprotein(a) has regions closely related (homologous) to plasminogen. Plasminogen breaks down clot (thrombolysis). Lp(a) may compete for plasminogen binding sites - in those with high Lp(a), this may promote clot formation when it shouldn't occur.
Plaque rupture is the most common mechanism for heart attack. When that endothelial "cap" breaks down from inflammation, it releases Tissue Factor and other thrombogenic compounds, activating thrombin, platelets, and the coagulation cascade. The fear for those with very high Lp(a) is that when they rupture a plaque, they do it big time - that snowball builds fast while plasminogen is being "stiff armed" by Lp(a).
Therefore, ASCVD events in patients with high Lp(a) are more likely to be of a "thrombotic" variety - meaning heart attack or stroke - and tend to be "premature," or earlier in life.
Inheritability
If Lp(a) is so bad, why is it so inheritable? Lp(a) is found in humans, Old World nonhuman primates, and the European Hedgehog. In prehistoric people it may have promoted wound healing at sites of vessel injury. In modern people it accelerates atherosclerosis and calcific aortic stenosis.
Lp(a) as a Risk Enhancer in the CPR Framework (2026)
The 2026 ACC/AHA guidelines incorporate elevated Lp(a) into the Personalized Risk Assessment framework. Per Table 13 of the guideline, Lp(a) ≥ 125 nmol/L or ≥ 50 mg/dL is listed as a formal risk enhancer that should be considered in the "Personalize" step of the Collaborative Risk Reduction (CPR) approach, allowing clinicians to adjust treatment intensity based on presence of elevated Lp(a).
Current Treatments for Lp(a)-Associated Risk
Until recently, all we could do to mitigate the additional risk from elevated Lp(a) was to target other modifiable risk factors more aggressively than we might otherwise. This landscape is now changing rapidly.
Therapies NOT Recommended for Lp(a) Lowering
Niacin
Does lower Lp(a), but has fallen out of favor after two major trials failed to show clinical benefit:
- The NHLBI-funded AIM-HIGH trial (2011) showed no clinical benefit beyond statins despite improvements in HDL-C (not surprisingly as we discuss elsewhere in What's Your ApoB?) and triglycerides.
- The HPS2-THRIVE trial (2014) showed no benefit but significant side effects including diabetes, GI upset, musculoskeletal problems, infection, and bleeding.
Estrogen
Modestly lowers Lp(a), but the potential side effects of hormone replacement therapy do not justify its use for this indication.
PCSK9 Inhibitors and Lp(a) — Now Class 1 for ASCVD (2026)
PCSK9 inhibitors do lower Lp(a) (~25-30%), and the 2026 ACC/AHA guidelines now recommend them specifically for patients with ASCVD and elevated Lp(a) not at LDL-C goal (Class 1, LOE B-R). This is a major upgrade from prior years where PCSK9 use for Lp(a) was considered secondary.
The rationale comes from favorable subgroup analysis data from the FOURIER trial (Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk) and the ODYSSEY OUTCOMES trial (Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering), where those at the highest levels of baseline Lp(a) had a greater absolute risk reduction compared with those with the lowest Lp(a) levels. While the Lp(a) reduction (~25-30%) is modest compared to what we expect from upcoming therapies, it is clinically meaningful in the context of established disease.
Lp(a) Apheresis — FDA-Approved Option
For severe Lp(a) elevation with progressive cardiovascular disease despite maximal lipid-lowering therapy, Lp(a) apheresis has been FDA-approved for patients with Lp(a) ≥ 60 mg/dL. This removes Lp(a) directly from the blood through extracorporeal filtration, reducing levels by 60-80% per session. It requires ongoing treatment (weekly to monthly depending on rebound kinetics) and is typically reserved for patients with very high Lp(a) and documented disease progression despite other measures.
Resmetirom (Rezdiffra) — An Emerging Partial Lp(a) Lowering Signal
Secondary analyses from the MAESTRO Phase 3 program and real-world data presented at EASL 2026 revealed that resmetirom (Rezdiffra) — FDA-approved for MASH with significant fibrosis — drove 37.5% of patients starting above Lp(a) 50 mg/dL below that threshold on background statin therapy — and 62.5% of statin-naive patients reached that same target by week 52. This is clinically meaningful because statins largely cannot lower Lp(a) and may even modestly raise it. Resmetirom is a thyroid hormone receptor-β agonist and is not indicated primarily as an Lp(a)-lowering therapy, but for patients with comorbid MASH and elevated Lp(a), this cardiohepatic benefit deserves consideration alongside its liver fibrosis indication. It is not a substitute for dedicated Lp(a)-lowering agents in patients without MASH. See also: “Barking Up the Wrong Tree” — MASLD/MASH.
2026: The Year Lp(a) Got Its First Real Answer — And It Was Complicated
Multiple drugs targeting Lp(a) have been advancing toward phase 3 readouts, and 2026 was set to deliver the first cardiovascular outcomes trials (CVOTs) in this space. The first of those trials has now reported: in September 2026, pelacarsen's Lp(a)HORIZON trial missed its primary endpoint (see below). This is a real setback, not a footnote — but it is one data point on one drug, not a verdict on the entire Lp(a)-lowering drug class. Several other agents, with different mechanisms and larger Lp(a) reductions, still have outcomes data to report.
According to the ACC Feature on Lp(a), the Cleveland Clinic Journal of Medicine, and coverage from the National Lipid Association 2025 Meeting, here's where we stand:
| Drug | Company | Type | Lp(a) Reduction | Route | Trial (n) | Expected Results |
|---|---|---|---|---|---|---|
| Pelacarsen | Novartis / Ionis | ASO | ~80% | SQ monthly | Lp(a)HORIZON (8,323) | Missed primary endpoint (Sep 2026) |
| Olpasiran | Amgen | siRNA | ~94–95% | SQ q12 weeks | OCEAN(a)-Outcomes (7,200) | Late 2026 ★ |
| Lepodisiran | Eli Lilly | siRNA | ~94% | SQ q24–48 weeks | ACCLAIM-Lp(a) (16,700) | 2027–2028 |
| Zerlasiran | Silence Therapeutics | siRNA | >90% | SQ q16–24 weeks | ALPACAR-360 (Ph2) | Phase 3 pending partner |
| Muvalaplin | Eli Lilly | Small molecule | ~63–65% | Oral daily | MOVE-Lp(a) (10,450) | 2031 |
Color key: Blue = Antisense Oligonucleotide (ASO) | Green = Small Interfering RNA (siRNA) | Gold = Oral Small Molecule | ★ = CVOT results expected 2026
ASO = Antisense Oligonucleotide | siRNA = Small Interfering RNA | SQ = Subcutaneous
Antisense Oligonucleotides (ASOs)
Pelacarsen (Novartis/Ionis) — Update: Lp(a)HORIZON Missed Its Primary Endpoint (September 2026)
An ASO that inhibits apolipoprotein(a) production by targeting its messenger RNA. Phase 2 demonstrated ~80% reduction in Lp(a) with monthly subcutaneous injections. The Lp(a)HORIZON trial was a phase 3 CVOT of 8,323 patients with established CVD and Lp(a) ≥70 mg/dL — the first cardiovascular outcomes trial ever completed for an Lp(a)-lowering therapy. On September 4, 2026, Novartis and Ionis announced topline results: despite substantially lowering Lp(a) (consistent with earlier-phase data), pelacarsen did not meet its primary endpoint — a composite of cardiovascular death, nonfatal MI, nonfatal stroke, and urgent coronary revascularization — in either the overall population (Lp(a) ≥70 mg/dL) or the pre-specified higher-risk subpopulation (Lp(a) ≥90 mg/dL). Safety was reassuring, with no new signals identified. Full data will be presented at an upcoming medical congress.
This is a genuinely disappointing result and the biggest Lp(a) story of the year, but it does not by itself settle the question of whether lowering Lp(a) reduces cardiovascular events. As lipidologist Pablo Corral, MD has pointed out, several open questions temper how much should be extrapolated from this one trial: participants were already on intensive background secondary-prevention therapy (LDL-C ~65 mg/dL, antiplatelet therapy, aggressive risk-factor control), which may have left less "modifiable" residual risk for Lp(a) lowering to act on; treatment began only after ASCVD was already established, whereas genetic (Mendelian randomization) evidence for causality reflects a lifetime of exposure; event rates were lower than projected, which both slows a trial's ability to detect a true effect and may itself suggest contemporary care has narrowed the risk pelacarsen could modify; and Lp(a) concentration may be an imperfect surrogate for its most pathogenic cargo (oxidized phospholipids), meaning two people with identical Lp(a) levels may not carry identical biological risk. Pre-specified analyses in the highest-Lp(a) subgroup and of total/recurrent events (rather than just time-to-first event) will be worth watching once full data are presented.
What this means for now: pelacarsen is very unlikely to reach approval on this dataset, and the failure raises the bar of evidence the entire Lp(a)-lowering drug class will need to clear. It does not change today's guideline-directed care: Lp(a) screening remains Class 1, and PCSK9 inhibitors remain Class 1 for ASCVD patients with elevated Lp(a) not at LDL-C goal. The next major readout to watch is Amgen's olpasiran (OCEAN(a)-Outcomes), expected late 2026 — a different drug class (siRNA vs. ASO) with a larger Lp(a) reduction, which may or may not show the same result.
Small Interfering RNA (siRNA)
Olpasiran (Amgen)
A siRNA that blocks Lp(a) production by inducing degradation of apolipoprotein(a) mRNA. Phase 2 results from OCEAN(a)-DOSE showed ~94-95% reduction in Lp(a) at 36 weeks with quarterly dosing. The OCEAN(a)-Outcomes trial (TIMI 75) enrolls 7,200 patients. Results expected late 2026.
Lepodisiran (Eli Lilly)
A siRNA producing durable reductions with infrequent dosing. Phase 2 showed ~94% reduction in Lp(a) sustained through day 360 after a single dose (Cleveland Clinic Newsroom). The ACCLAIM-Lp(a) trial enrolls up to 16,700 patients — the largest of all ongoing Lp(a) studies. Results expected 2027-2028.
Zerlasiran (Silence Therapeutics)
A siRNA that completed the phase 2 ALPACAR-360 study with >90% Lp(a) reduction. The company has received FDA feedback for phase 3 but initiation depends on finding a development partner.
Oral Small Molecule
Muvalaplin (Eli Lilly)
An oral small molecule that inhibits Lp(a) formation by blocking the initial interaction between apo(a) and apoB. Phase 2 (KRAKEN trial) showed ~63-65% reduction with once-daily oral dosing. The MOVE-Lp(a) trial enrolls 10,450 patients. While less dramatic reduction than siRNA agents, it offers the significant advantage of oral administration. Results expected 2031.
Obicetrapib (NewAmsterdam Pharma)
A CETP inhibitor whose primary effect is LDL-C lowering, but which also produces a meaningful Lp(a) reduction as a secondary benefit. In the Phase 3 BROADWAY trial (2,530 patients with ASCVD and/or heterozygous familial hypercholesterolemia), obicetrapib 10 mg daily reduced LDL-C by 33% and Lp(a) by ~45% on top of maximally tolerated statin therapy. An exploratory pooled analysis across Phase 3 trials showed a 32% reduction in MACE, though this signal is not yet confirmed in a dedicated outcomes trial. Unlike earlier CETP inhibitors (torcetrapib, dalcetrapib, evacetrapib), obicetrapib has shown no off-target toxicity to date. The dedicated cardiovascular outcomes trial (PREVAIL) reads out in late 2026 and will determine whether this exploratory signal holds up — until then, obicetrapib should be considered investigational, not a proven Lp(a)-lowering therapy.
The Big Question: Will Lp(a) Lowering Reduce Events? — Still Open After HORIZON
For years, no published outcome trial had tested whether Lp(a) lowering reduces major cardiovascular events. Mendelian Randomization studies suggested substantial Lp(a) lowering (>50-100 mg/dL) would be required for meaningful risk reduction — and pelacarsen delivered reductions in that range, yet Lp(a)HORIZON still missed its primary endpoint (September 2026). That is a genuinely important negative result, and it means the "if we lower it enough, events will fall" hypothesis is no longer a safe assumption.
It does not mean the hypothesis is dead. Genetic causality (decades of lifelong exposure via Mendelian randomization) and short-term pharmacological intervention in patients already on intensive secondary prevention are not the same test, and a single trial — even a well-powered one — can fail for reasons other than "Lp(a) lowering doesn't work" (wrong population, wrong timing, wrong biological cargo targeted, insufficient residual risk left to modify). The remaining CVOTs — olpasiran's OCEAN(a)-Outcomes (late 2026) and lepodisiran's ACCLAIM-Lp(a) (2027–2028) — use different drug classes (siRNA) with even larger Lp(a) reductions, and will be the next real tests of whether this is a drug-specific result or a class-wide one.
The honest framing for patients and clinicians right now: Lp(a) is still a real, causal, genetically-driven risk factor worth knowing about — that part of the story hasn't changed. What's now uncertain is whether, when, in whom, and by how much it needs to be lowered pharmacologically to change outcomes. Don't let HORIZON's result talk you out of testing Lp(a) or optimizing every other modifiable risk factor aggressively in someone who has it — that guidance stands regardless of how the drug pipeline shakes out.
Lp(a) and Aortic Stenosis
Beyond atherosclerosis, elevated Lp(a) is strongly associated with accelerated calcific aortic valve disease. Patients with Lp(a) ≥ 50 mg/dL have a 3x higher risk of aortic stenosis. With aortic stenosis incidence projected to triple by 2050, this may become an equally important target for Lp(a)-lowering therapy. See our article on aortic valve disease for more details (cross-link when available).
The Bottom Line
Lp(a) may be little, but it punches well above its weight class — the original "Little Napoleon Complex."
About 1 in 5 of us have elevated Lp(a), making it the most common genetic lipid disorder causal to atherosclerosis. Yet fewer than 2% of those with lipid panels have ever been tested. This has to change — and now, with Class 1 universal screening from the 2026 ACC/AHA guidelines, it will.
Until recently, all we could do was optimize other risk factors. 2026 was supposed to be the year direct Lp(a)-lowering therapies proved themselves in outcomes trials — and the first one to report, pelacarsen's Lp(a)HORIZON, missed its primary endpoint in September 2026 despite substantially lowering Lp(a). That's a real setback, not a footnote, and it means this "once-untreatable risk factor becomes treatable" story is now more uncertain than it looked a year ago. PCSK9 inhibitors remain Class 1 for ASCVD with elevated Lp(a). Lp(a) apheresis remains available for severe cases. And two more late-stage drugs with different mechanisms and even larger Lp(a) reductions — olpasiran and lepodisiran — still have outcomes data to report over the next 1–2 years, which will tell us whether HORIZON was a drug-specific result or something more fundamental.
If you have heart disease, a family history of premature heart disease, or want to understand your complete cardiovascular risk profile — ask for your Lp(a) to be checked. If it's elevated, inform your family members so they can be tested too.
Don't let your Little Napoleon fly under the radar.
Expert Sources & Landmark References
- 2026 ACC/AHA/NLA Dyslipidemia Guidelines — JACC
- Pablo Corral, MD (@drpablocorral) — Lipidologist whose post-HORIZON analysis shaped our September 2026 update above
- Sam Tsimikas, MD (@Lpa_Doc) — Leading voice on Lp(a) pathophysiology
- Thomas Dayspring, MD (@Drlipid) — Lipid metabolism expert
- Nathan Wong, PhD — Co-authored Lp(a) clinician awareness survey
- European Society of Cardiology (2019) — Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement